ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myelodysplastic Syndromes
Myeloid Leukemia
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia (AML) trials near Hanyang, Seoul, KOR:

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Seoul, Seoul, South Korea and 33 other locations

Locations recently updated

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse aft...

Enrolling
Acute Myeloid Leukemia
Drug: Pivekimab Sunirine

Phase 1

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, South Korea and 9 other locations

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) (REVIVAL)

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia...

Enrolling
Acute Myeloid Leukemia
Drug: Pivekimab Sunirine
Drug: Azacitidine

Phase 2, Phase 3

AbbVie
AbbVie

Seoul, Seoul Teugbyeolsi, South Korea and 10 other locations

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: Daunorubicin
Drug: Azacitidine (AZA)

Phase 3

Kura Oncology

Seoul, Seoul-T'Ukpyolsi, South Korea and 105 other locations

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation (REVEAL-ND NPM1)

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain ...

Enrolling
Acute Myeloid Leukemias
Drug: Revumenib
Drug: Intensive Chemotherapy Regimen

Phase 3

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Seoul, South Korea and 82 other locations

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute...

Enrolling
AML With Gene Mutations
Drug: ZE46-0134

Phase 1

Lomond Therapeutics Holdings, Inc.

Seoul, South Korea and 22 other locations

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refr...

Active, not recruiting
Acute Myeloid Leukemia
Drug: TL-895
Drug: KRT-232

Phase 1, Phase 2

Telios Pharma

Seoul, Korea, Republic of and 34 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Seoul, South Korea and 48 other locations

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Drug: Azacitidine
Drug: LY3410738

Phase 1

Lilly
Lilly

Seoul, Seoul-teukbyeolsi [Seoul], South Korea and 36 other locations

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (cAMeLot-2)

VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation...

Enrolling
Leukemia, Myeloid, Acute
Drug: Venetoclax (VEN)
Drug: Azacitidine (AZA)

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seoul, South Korea and 256 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems